$13,025.31 ownership Payment -- Eli Lilly and Company to Dr. Amy Phillips
Oncology Physician Amy Phillips Receives $13,025 Ownership Interest from Eli Lilly
This page provides a detailed analysis of a $13,025.31 ownership payment from Eli Lilly and Company to Dr. Amy Phillips. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $13,025.31 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Eli Lilly and Company |
| Physician | Dr. Amy Phillips |
| NPI Number | 1341745042 |
| Physician Specialty | Oncology |
| Location | Springfield, IL |
| Date of Payment | 2025-02-09 |
| Related Drug/Device | Imbruvica |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Eli Lilly and Company made a $13.0K ownership payment to Amy Phillips, a Oncology specialist in Springfield, IL. The payment was associated with Imbruvica. Amy Phillips received a significant ownership interest payment of $13,025.31 from Eli Lilly and Company. This payment is categorized as an 'Ownership or Investment Interest', indicating a potential financial stake beyond direct compensation. The payment is associated with Imbruvica, a drug commonly used in Oncology.
Patient Guidance: What This Payment Means for You
This record indicates a financial relationship where a physician may have an ownership stake in a company or product. It's important to understand the nature of this relationship and how it might align with patient care decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interest payments can vary widely. For an Oncology specialist, such payments might relate to investments in pharmaceutical companies or medical device manufacturers involved in cancer treatment.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug/device manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- eli-lilly
- oncology
- imbruvica
- physician-payment
- cms-open-payments
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $13.0K payment for?
This was a ownership payment of $13.0K from Eli Lilly and Company to Amy Phillips, categorized as "Ownership or Investment Interest". It was associated with Imbruvica. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Amy Phillips accept pharmaceutical money?
Yes, Amy Phillips received this $13.0K payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amy Phillips's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $13.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Amy Phillips's relationship with Eli Lilly and Company?
The payment date is in the future (February 9, 2025), which is unusual for reported payments. This $13.0K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment amount is substantial for an ownership interest, suggesting a significant investment.
What should patients do after learning about this payment?
This record indicates a financial relationship where a physician may have an ownership stake in a company or product. It's important to understand the nature of this relationship and how it might align with patient care decisions.
What else should I know about this ownership payment?
The specific nature of the ownership interest is not detailed in this record.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.